Comparisons
How we compare — honestly.
Straight comparisons against the incumbents and the do-it-yourself path. We say where the alternative is genuinely strong, then where a cited, auditable, white-label verdict changes the math for a CRO.
vs Citeline, IQVIA, and in-house teams.
Pick a comparison
The alternatives, taken seriously.
Three routes a CRO realistically takes to a feasibility answer. Each page lays out the same dimensions so you can compare like for like.
incumbent feasibility & intelligence vendor
vs Citeline
Citeline (Norstella) is a deep, well-established intelligence suite.
See the comparisonglobal CRO & data/analytics provider
vs IQVIA
IQVIA is a global CRO and data powerhouse with feasibility and study-planning offerings bundled into broader services.
See the comparisonbuilding feasibility internally
vs An in-house feasibility team
Plenty of CROs and sponsors run feasibility manually — analysts pulling ClinicalTrials.gov, building site lists, and assembling a deck.
See the comparisonHow each page is built
Same structure, every comparison.
No cherry-picked feature grid. Every comparison runs the same three blocks, in the same order.
Where the alternative is strong
Each page opens by saying what the alternative genuinely does well. If the honest answer is "buy theirs", we would rather you read that here than find it out in month three.
Where we differ
Then the specific, checkable differences — the things you can hold us to in a bid defence, not adjectives.
A capability table
Side by side on the dimensions that decide it: turnaround per protocol, citation provenance, reproducibility, audit trail, deployment model, and pricing shape.
These comparisons reflect our understanding of typical offerings and are provided in good faith; vendor capabilities change, so verify current details with each provider. All product names, logos, and trademarks are the property of their respective owners and are used for identification only.
See a verdict you can actually check.
Send us a protocol — or just a molecule and an indication. We'll return a fully cited feasibility assessment you can trace, line by line, back to public data — yours to defend in a bid, take to your board or investment committee, or hand to a regulator.